2018

• Received the "Asia's Best CMO" awarded by Biologics Manufacturing Asia (BMA).
• EG12014 was approved for phase III clinical trial by US FDA and Taiwan FDA.

2017

• Held beam-raising ceremony for Zhubei plant
• Received "2017 Biomarker Industry Potential Benchmark Award" by Taiwan Bio Industry Organization
• EG12014 European Phase I clinical trial study showed positive results.
• Received "Grand Winner of Best Bioprocess Excellence in Taiwan” by Biologics Manufacturing Asia (BMA)
• Antibody Drug Conjugate platform received excellence award by Biologics Manufacturing Asia (BMA)
• Received official certificate from Japan MHLW of foreign manufacturer of biologics, which granted biologics manufactured by EirGenix in Taiwan.

2016

• EG12014 was approved for the European Phase I clinical trial.
• Received financial support around NT$850 million for Zhubei plant
• Began Zhubei plant’s construction
• EirGenix cooperate stock was officially listed on Stock Exchange (6589).

2015

• Completed follow-up inspection by Taiwan FDA
• Applied EG12014 for the European Phase I clinical trial.
• Received the Gold Prize for in "Biomedical and New Agricultural Industry Award".

2014

• EirGenix's received PIC/S GMP certificate from Taiwan FDA.

2013

• Predecessor's (DCB-Biopharmaceutical Pilot Plant) microbial production facility received cGMP certificate from Taiwan FDA.
• Acquired DCB-biopharmaceutical pilot plant.
• Updated the US FDA Type V Drug Master File and Taiwan FDA registration information.
• Completed follow-up inspection by the Taiwan FDA

2012

• EirGenix Inc. was founded.

2011

• Predecessor (DCB-Biopharmaceutical Pilot Plant) received BioPharm 2011 Asia Best CMO Award.
• Predecessor (DCB-Biopharmaceutical Pilot Plant) completed follow-up inspection by Taiwan FDA.

2008

• Predecessor (DCB-Biopharmaceutical Pilot Plant) completed follow-up inspection by Taiwan FDA.

2006

• Predecessor (DCB-Biopharmaceutical Pilot Plant) registered Drug Master File to US FDA (DMF no. 19164).
  NOTE: Type V DMF is used for sterile manufacturing plants and contract facilities for biotech products.

2005

• Predecessor (DCB-Biopharmaceutical Pilot Plant) received cGMP certificate from Taiwan FDA.